You are here

Norethindrone, Generic Equivalent of Ortho-Micronor, Now Available

CORONA, Calif., June 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that it has launched JOLIVETTE™ (norethindrone tablets), a brand equivalent of the oral contraceptive Ortho-Micronor®, marketed by Ortho-McNeil Pharmaceutical, Inc. In 2002, Ortho-Micronor® had annual sales of approximately $51 million. JOLIVETTE™ is indicated for the prevention of pregnancy.

"Watson is known for having the broadest oral contraceptive portfolio in the pharmaceutical industry," said Joseph Papa, Watson's President and Chief Operating Officer. "The launch of JOLIVETTE™ marks our fourth oral contraceptive launch in 2003, bringing Watson's oral contraceptive product offerings to 15 products and 23 strengths."

More Headlines

More drugs or more costly drugs are being prescribed, industry trade group says
Risk approaches 13% for women who fall ill early in pregnancy
Alexion announces positive top-line results for ALXN1210 in PNH
Increased risk of high-frequency hearing loss pegged at 60%
Janssen drug targets metastatic urothelial cancer, marked by poor outcomes
Researchers say this real-world study in Canada should also apply to the U.S.
The results from a seven-year study were “entirely unexpected”
Generic competition pushed back to at least mid-2018
Report identifies critical need to minimize financial toxicity and increase access